Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.29 +0.28 (+0.04%)
Streaming Delayed Price Updated: 1:30 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
3 Biotech Stocks to Buy Now: June 2024
These are the three best biotech stocks to buy for long-term returns and portfolio stability due to their target patient populations, 
Via InvestorPlace
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Lawsuit Could Challenge Trust In Ozempic And Other Popular Weight Loss Drugs
Weight loss drug manufacturers Novo Nordisk and Eli Lilly are being challenged in court. The companies are accused of failing to properly warn patients about associated risks. 
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
(LLY) - Analyzing Eli Lilly and Co's Short Interest
Via Benzinga
Here's How Much $1000 Invested In Eli Lilly and Co 10 Years Ago Would Be Worth Today
Via Benzinga
Spotlight on Eli Lilly and Co: Analyzing the Surge in Options Activity
Via Benzinga
Pre-Market Movers - June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers. 
Via Talk Markets
Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss
As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of the drug called petrelintide. 
Via Benzinga
Hype Busters: 3 Overvalued Stocks Ready for a Reality Check
Discover three overvalued stocks that have completely lost touch with reality, with growth assumptions destined for disappointment. 
Via InvestorPlace
Nestle Carefully Targets Weight-Loss Drug Users with New Food Line
Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addressing regulatory concerns and focusing on marketing through social media. 
Via Benzinga
Forget Eli Lilly, Buy This Magnificent Biotech Stock Instead
Lilly is a good pick...but this one is better. 
Via The Motley Fool
Eli Lilly Has a New Drug That Could Push the Stock Higher
The Alzheimer’s treatment market is large and expected to grow. 
Via The Motley Fool
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover. 
Via Benzinga
Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for June 2024
Investors hunting for stocks that will provide big gains should consider these top-rated growth stocks that have upside potential. 
Via InvestorPlace
Eli Lilly's Growth Prospects Just Got a Huge Upgrade
The company's promising Alzheimer's drug could soon obtain approval from regulators. 
Via The Motley Fool
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of... 
Via Benzinga
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs 
Via MarketBeat
Topics Economy
Exposures Interest Rates
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors. 
Via MarketBeat
Exposures Product Safety
Eli Lilly Stock Analysis: Buy, Hold, or Sell?
Eli Lilly is ramping up manufacturing to meet the soaring demand for its innovative medicines. 
Via The Motley Fool
Eli Lilly Hits All-Time High, Named To Big Cap 20 List: Check These Lists For Best Stocks To Buy
Eli Lilly stock has been on an astounding run. In 2009 its stock sold for 27.21 a share. It closed Tuesday at 891.46, up 3,149% from 2009. 
Via Investor's Business Daily
The Best Biotech Stock to Invest $1,000 in Right Now
This stock may not be a slam dunk, but it's looking very promising. 
Via The Motley Fool
3 Strong Buy Stocks for a Sizzling Summer Rally
Investors can take a deep breath before the next earnings season, but they should still invest in equities, including these three gems hiding in plain sight 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment. 
Via Investor's Business Daily
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for... 
Via Benzinga
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.
Eli Lilly just drizzled on Madrigal Pharmaceuticals' parade. 
Via The Motley Fool
Will Walmart Reach a Trillion-Dollar Market Cap by 2030?
This seemingly unlikely non-tech name quietly deserves to be on the list of contenders that could achieve the feat in the foreseeable future. 
Via The Motley Fool
Mounjaro Is Targeting Another Multibillion-Dollar Market: Is Eli Lilly Stock a Buy?
The company has too many weapons at its disposal. 
Via The Motley Fool
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster
The drugmaker continues to make headlines for all the right reasons. 
Via The Motley Fool
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.